Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Small Cell Lung Carcinoma 2Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Rituximab 168Cyclophosphamide 142Peripheral Blood Stem Cell Transplantation 84fludarabine phosphate 68Filgrastim 64Etoposide 63Radiotherapy 55Vincristine 47Prednisone 45Mycophenolic Acid 44Melphalan 40Whole-Body Irradiation 39Cyclosporine 39Busulfan 39Tacrolimus 36Doxorubicin 34Cytarabine 33Lenalidomide 29Carmustine 28Antilymphocyte Serum 28Methotrexate 27Methylprednisolone 26Bortezomib 26Bendamustine Hydrochloride 26sargramostim 21ibritumomab tiuxetan 20obinutuzumab 19ibrutinib 18fludarabine 18Dexamethasone 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, Follicular × obatoclax × Clear all
NCT00427856 2016-07-22

Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
7 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡